New drug combo aims to outsmart resistant cancers
NCT ID NCT05082259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight cancer. About 61 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX660 (Tolinapant) and Pembrolizumab
What this could lead to
If successful, this could point toward a new combination therapy for cancers that don't respond to current treatments.
What could go wrong
This is an early Phase 1 trial with only 61 participants, so safety and dosing are still being figured out. It may not work in larger groups or for all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Trust
Cambridge, CB2 0QQ, United Kingdom
-
The Royal Marden NHS Foundation Trust - Drug Development Unit
Sutton, SM2 5PT, United Kingdom
-
The Royal Marsden NHS Foundation Trust - Breast Unit
Sutton, SM2 5PT, United Kingdom